During Wednesday’s Morning trade, Shares of Mylan NV (NASDAQ:MYL), gained 0.13% to $55.36.
Mylan N.V., declared the U.S. launch of Linezolid Tablets, 600 mg, which is the generic version of Pfizer’s Zyvox® Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated in adults and children for the treatment of certain infections caused by susceptible Gram-positive bacteria.
Linezolid Tablets, 600 mg, had U.S. sales of about $457.8 million for the 12 months ending Sept. 30, 2015, according to IMS Health.
Presently, Mylan has 269 ANDAs pending FDA approval representing $100.8 billion in annual brand sales, according to IMS Health. Fifty of these pending ANDAs are potential first-to-file opportunities, representing $35.6 billion in annual brand sales, for the 12 months ending June 30, 2015, according to IMS Health.
Mylan N.V., through its auxiliaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch forms, in addition to active pharmaceutical ingredients (APIs).
Shares of Walgreens Boots Alliance Inc (NASDAQ:WBA), declined -0.34% to $86.52, during its current trading session.
The Walgreens Flu Index™ is a weekly report developed to provide state- and market-specific information, and ranking of those experiencing the highest incidences of influenza across the country. The Flu Index does not provide data measuring actual levels or severity of flu activity, but rather, illustrates which populations are experiencing the most incidences each week based on Index methodology.
With the ability to generate hyper-local data across most U.S. markets, the Flu Index is an online, interactive resource allowing anyone to search and find information regarding the most current state of influenza in their community.
Walgreens Boots Alliance, Inc. operates as a pharmacy-led health and wellbeing company. The company operates through three segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale.
Finally, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), lost -1.48%, and is now trading at $2.00.
Park Lane Advisor has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (ARNA), Compugen Ltd (CGEN), ChemoCentryx Inc. (CCXI), and Concert Pharmaceuticals Inc. (CNCE). Free research report on Arena Pharma can be accessed at http://www.parklaneadvisor.com/ On Tuesday, December 22, 2015, the NASDAQ Composite ended at 5,001.11, up 0.65%, the Dow Jones Industrial Average advanced 0.96%, to finish the day at 17,417.27, and the S&P 500 closed at 2,038.97, up 0.88%. The gains were broad based as all the sectors ended the session in positive. Register for your complimentary reports at the links given below.
On Tuesday, shares in Arena Pharmaceuticals Inc. recorded a trading volume of 2.25 million shares, lower than their three months average volume of 3.43 million shares. The stock ended the day 3.94% lower at $1.95. Arena Pharmaceuticals Inc.’s stock has lost 6.25% in the last one month, 23.83% in the previous three months and 43.80% on YTD basis. The company is trading below its 50-day and 200-day moving averages by 4.83% and 42.77%, respectively. Furthermore, shares of Arena Pharmaceuticals Inc. have a Relative Strength Index (RSI) of 47.80.
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight administration in adults.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
